Oxygenta Pharma

{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "55.43",
    "chg": -2.41,
    "chgp": "-4.17%",
    "dir": -1,
    "prev_price": "57.84",
    "mcapval": "211.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE102E01018",
    "curr_date": "May 15",
    "curr_time": "",
    "bse_nse_vol": "5.23 k",
    "exc_status": "Active",
    "traded_date": "May 15, 2026",
    "traded_date_str": "2026 05 15",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3981512",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/OxygentaPharmac_mojoScore_3981512.png",
        "date": "2026-05-08 10:10:22",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3964278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/OxygentaPharmac_mojoScore_3964278.png",
        "date": "2026-04-27 10:10:25",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3949152",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/OxygentaPharmac_mojoScore_3949152.png",
        "date": "2026-04-16 10:10:16",
        "description": "Oxygenta Pharmaceutical Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3933253",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/OxygentaPharmac_mojoScore_3933253.png",
        "date": "2026-04-05 10:10:11",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 April 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Markets Rally, But Oxygenta Pharmaceutical Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-falls-to-52-week-low-of-rs453-3928529",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/OxygentaPharmac_priceRelatedfactors_3928529.png",
        "date": "2026-04-01 09:59:54",
        "description": ""
      },
      {
        "title": "Markets Rally, But Oxygenta Pharmaceutical Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-stock-hits-52-week-low-amidst-continued-downtrend-3924463",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/OxygentaPharmac_priceRelatedfactors_3924463.png",
        "date": "2026-03-30 11:19:08",
        "description": ""
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3909790",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/OxygentaPharmac_mojoScore_3909790.png",
        "date": "2026-03-24 10:10:16",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharmaceutical-ltd-is-rated-strong-sell-3886687",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/OxygentaPharmac_mojoScore_3886687.png",
        "date": "2026-03-12 10:10:18",
        "description": "Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Stock Falls to 52-Week Low of Rs.46",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-stock-falls-to-52-week-low-of-rs46-3869473",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/OxygentaPharmac_priceRelatedfactors_3869473.png",
        "date": "2026-03-04 11:28:43",
        "description": "Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46 on 4 March 2026, marking a significant downturn amid a challenging year for the company. This latest low reflects ongoing pressures on the stock, which has underperformed the broader market and its sector over the past twelve months."
      }
    ],
    "total": 228,
    "sid": "798135",
    "stock_news_url": "https://www.marketsmojo.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "27-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Oxygenta Pharmaceutical Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24110TG1990PLC012038</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>1073089940.31</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NIL</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: KUMKUM BAJAJ <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: cs@decipherlabs.in</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD REDDY BATTINAPATLA <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: prasadb@virupaksha.com</div> </div> <div> <br/> Date: 27/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "27-Apr-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Oxygenta Pharmaceutical Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24110TG1990PLC012038</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>FY 2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>NIL</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>NIL</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>NIL</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>FY 2025-26 2024-25</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>KUMKUM BAJAJ</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>PRASAD REDDY BATTINAPATLA</td></tr> <tr><td>Designation : -</td><td>CHIEF FINANCIAL OFFICER</td></tr></table><div> <br/> Date: 27/04/2026<br/><br/></div>",
      "source": "BSE"
    },
    {
      "caption": "Compliance As Per Regulation 74(5) Of SEBI (Depositories And Participants) Regulations 2018 For The Quarter Ended 31St March 2026",
      "datetime": "15-Apr-2026",
      "details": "Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-05-08 10:10:22

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-04-27 10:10:25

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-04-16 10:10:16

Oxygenta Pharmaceutical Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-04-05 10:10:11

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Markets Rally, But Oxygenta Pharmaceutical Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-04-01 09:59:54

Read full news article

Markets Rally, But Oxygenta Pharmaceutical Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-03-30 11:19:08

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-03-24 10:10:16

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Oxygenta Pharmaceutical Ltd is Rated Strong Sell

2026-03-12 10:10:18

Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Oxygenta Pharmaceutical Ltd Stock Falls to 52-Week Low of Rs.46

2026-03-04 11:28:43

Oxygenta Pharmaceutical Ltd’s shares declined sharply to a new 52-week low of Rs.46 on 4 March 2026, marking a significant downturn amid a challenging year for the company. This latest low reflects ongoing pressures on the stock, which has underperformed the broader market and its sector over the past twelve months.

Read full news article

View All News